Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

>Drug Interactions:

  • Renal clearance of lithium is reduced by diuretics, such as chlorthalidone, increasing the risk of lithium toxicity.
  • Monitor renal function periodically in patients receiving EDARBI or EDARBYCLOR and NSAIDs who are also elderly, volume-depleted (including those on diuretics), or who have compromised renal function, as deterioration of renal function, including possible acute renal failure, may result. These effects are usually reversible. NSAIDs may interfere with antihypertensive effect.
  • Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Please click here for complete EDARBI Prescribing Information or here for complete EDARBYCLOR Prescribing Information.

Indications and Usage
EDARBI and EDARBYCLOR are indicated for the treatment of hypertension to lower blood pressure. EDARBI is an angiotensin II receptor blocker (ARB) and EDARBYCLOR is an ARB and a thiazide-like diuretic combination. EDARBYCLOR may be used if a patient is not adequately controlled on monotherapy or as initial therapy if multiple drugs are needed to help achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. There are no controlled trials demonstrating risk reduction with EDARBI or EDARBYCLOR, but trials with chlorthalidone and at least one pharmacologically similar drug to azilsartan medoxomil have demonst
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Medela announced today that it has reached a five-year ... the exclusive distributor of the ABC Enteral Feeding Pump ... Pump. Through this agreement, Medela will be in a ... by offering a comprehensive set of products and programs. ... to the delivery of human milk to at-risk infants. ...
(Date:9/23/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announces the ... and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. to ... connection with the recently announced acquisition of greater ...
(Date:9/23/2014)... CARLOS, Calif. , Sept. 23, 2014 /PRNewswire/ ... company, today confirmed the initiation of human safety ... forms of addiction. A single dose of 18-MC, ... safety study conducted by Savant,s South American partner, ... experimental drug. Savant HWP plans to develop 18-MC ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... , SAN DIEGO, Nov. 6 Ardea Biosciences, Inc. ... the development of small-molecule therapeutics for the treatment of ... recent accomplishments and financial results for the third quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) , "Since our last ...
... Inc., in collaboration with scientists at the Centers for Disease ... of Hong Kong, announced today the publication of two articles ... studies suggest that DAS181 (Fludase ® ) may play a ... Pandemic Influenza A(H1N1) and drug-resistant influenza. , DAS181 is ...
Cached Medicine Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... cholesterol-lowering drugs while in the hospital for a hemorrhagic stroke ... than four times more likely to survive than people who ... People taking the commonly used drugs known as statins were ... to a rehabilitation facility, the study reports. When it ...
(Date:9/23/2014)... have published the first study to extensively characterize ... The Journal of Allergy and Clinical Immunology , ... has high levels of eosinophils in the blood ... mechanisms and has a gene expression pattern (transcriptome) ... disorder, eosinophilic esophagitis (EoE). , Eosinophilic gastrointestinal ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
(Date:9/23/2014)... a potential source of student diversity for medical ... however, there are significant challenges to enhancing the ... medical schools. The authors recommend that medical school ... be more inclusive of community college students. , ... Francisco and San Jose City College found that, ...
(Date:9/23/2014)... Affordable Care Act "Obamacare" was signed into ... the U.S. healthcare system since the 1960s. Designed to ... widely decried as an unwarranted intrusion into the affairs ... comparative study of healthcare systems in six Western countries, ... , supports a move away from privatized medicine toward ...
Breaking Medicine News(10 mins):Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:Medical students who attended community college likelier to serve poor communities 2Health News:Life, liberty, and the pursuit of healthcare? 2
... intensive therapy works well, study finds , THURSDAY, Aug. ... (RA) who respond poorly to standard treatment with methotrexate ... (TNF) blockers, a Swedish study suggests. , Previous research ... patients have a good response to methotrexate therapy and ...
... , , MISSION VIEJO, Calif., ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care ... quarter of fiscal year 2009. , , (Logo: ... Include: , , Total revenue was ...
... , , RANCHO CORDOVA, Calif., ... ), a leading supplier of innovative products for processing and storing ... BMC ("Res-Q") System, an automated cell processing medical device for the ... , , The Res-Q System processes bone ...
... American Health Assistance Foundation Researcher Is Featured Facilitator , ... Health Assistance Foundation and Asbury Methodist Village are partnering to host a ... Project to bring awareness to the community about this devastating disease, ... Part one of the Momentum in Science ...
... ... The Angelman Syndrome Foundation, www.angelman.org , announced the ... direct the organization,s rapidly increasing research funding. The ATRI will also ... scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. ...
... BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- , ... CHDX ), a leading,independent American provider ... Republic of China, today announced that the Company,s,Western-style ... a comprehensive, international-standard oncology program, called "New,Hope," at ...
Cached Medicine News:Health News:TNF Blockers May Help Some With Rheumatoid Arthritis 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 3Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 4Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 5Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 6Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 7Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 8Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 9Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 10Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 11Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 12Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 13Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 2Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 3Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 2Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 3Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
... 4, 8, or 12 channel pipettors. Angled ... nearly all of the solution. Corners have ... Made of natural virgin polystyrene containing no ... 152 mm L x 35 mm H ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
... for use with measuring pipettes, enables you to ... works with all types of glass or plastic ... to 100 mL.Gilsons Pipette Aid is equipped with ... protect the mechanism of the device from contamination ...
Application: Safe and convenient filling and dispensing of glass and plastic pipets....
Medicine Products: